The RIO study is looking at whether a new type of treatment can keep viral load undetectable without ART. This will involve asking all participants to stop ART for a short time.
The study will measure how long viral load stays undetectable without ART. It will also look at what happens to the HIV virus and immune system in blood samples. When virus becomes detectable in a blood test (viral rebound) you will be asked to re-start your ART.
- Professors Sarah Fidler and John Frater on the bNAb vaccinal effectCurrent Opinion in HIV and AIDS – May 2022 – Volume 17 – Issue 3 Our RIO Trial Chief Investigator Professor Sarah Fidler and […]
- Professor Sarah Fidler in the Shot & Chaser podcastJune 7, 2022 Listen to the latest Shot & Chaser podcast with our RIO Trial Chief Investigator, Professor Sarah Fidler, […]
- Nature publication: antibody therapy controls HIV for months in new clinical trialFindings from a clinical trial led by Rockefeller University scientists as reported by journal Nature highlight anti-HIV antibodies as a […]
RIO is funded by the Bill & Melinda Gates Foundation. Imperial College London is the Trial Sponsor and the trial is coordinated by Imperial College London, The University of Oxford and The Rockefeller University.